Mr. Goldfarb is a panel moderator and Mr.Melnick is a panelist for “What Hath It Wrought: Did the Financial Crisis Alter the Litigation & Enforcement Landscape”, Commercial Litigation panel, New York City Bar Association.
When Governor Andrew Cuomo delayed a decision on whether to renominate Victoria Graffeo to the state's Court of Appeals two weeks ago, he dismissed the idea that party politics might influence his choice.
Mr. Comstock is a panelist for Regulatory Compliance Association “SEC Initiates Flash Boy Regulations – A Comprehensive Analysis.”
You represent a defendant in a putative class action in federal court. The lead plaintiff’s potential damages are de minimis, although lead plaintiff’s counsel is seeking millions on behalf of the putative class. You believe that if you can defeat the lead plaintiff’s motion for class certification, the (soon-to-be former) lead plaintiff will lose settlement leverage and quickly settle its claim for a trivial amount. After all, you think, now that class certification has been denied, your client no longer has to worry about classwide damages, right? If only it were that easy.
Pharmaceutical giant GlaxoSmithKline was fined $490 million earlier today by a court in China for violations of Chinese anti-corruption law. The bribery conviction also included criminal sentences for individual executives, including a suspended prison sentence and an ordered deportation for GSK’s British former head of China operations.